Clinical Intervention Scenarios
Post-Resection mRNA Booster
CD8+ Cytotoxic T-Cell
Dendritic / APC (Spike Cross-Prime)
Glioblastoma Tumor Cell
M1 Microglia (Antitumor)
M2 Microglia (Immunosuppressive)
Vaccine Timing
21 days post-op
Booster Doses
2 doses
BBB Permeability Index
0.78
Anti-PD-1 Synergy
40%
Immunological Microstate
CD8+ Expansion
3.4x
Lysis Rate
4.8%/d
M1 Polarization
64.2%
CD8 Infiltration
320/mm²
Microenvironment State
Hot Infiltrated / Antitumor Polarized
Kaplan-Meier Survival Projection
N = 500 Cohort
Hazard Ratio (HR)
0.62
Log-Rank p
0.0032
Median OS Gain
+7.8 mo
2-Yr OS Gain
+18.5%